Drug Profile
Calcitonin transdermal - TransPharma
Alternative Names: Transdermal salmon calcitonin; ViaDerm-Calcitonin; ViaDor-CalcitoninLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator TransPharma Medical
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin receptor agonists; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Musculoskeletal pain; Osteoarthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Musculoskeletal-pain in Israel (Transdermal, Patch)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoarthritis in Israel (Transdermal, Patch)
- 20 Jul 2012 The European Medicines Agency recommended that due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .